Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer therapy

Organ-sparing precision treatment for muscle-invasive bladder cancer

Nature Medicine volume 29, pages 2709–2710 (2023)Cite this article

Subjects

The response to neoadjuvant treatment can be used to stratify individuals with muscle-invasive bladder cancer according to their risk of progression, enabling bladder-sparing approaches for some — and heralding a shift from the existing one-size-fits-all approach.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schema depicting organ-sparing precision treatment.

References

  1. Cercek, A. et al. New Engl. J. Med. 386, 2363–2376 (2022).

    Article  CAS  PubMed  Google Scholar 

  2. Chalabi, M. et al. Nat. Med. 26, 566–576 (2020).

    Article  CAS  PubMed  Google Scholar 

  3. Shabsigh, A. et al. Eur. Urol. 55, 164–174 (2009).

    Article  PubMed  Google Scholar 

  4. Galsky, M. D. Nat. Med. https://doi.org/10.1038/s41591-023-02568-1 (2023).

    Article  PubMed  Google Scholar 

  5. Necchi, A. et al. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.2174 (2023).

    Article  PubMed  Google Scholar 

  6. Funt, S. A. et al. J. Clin. Oncol. 40, 1312–1322 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rose, T. L. et al. J. Clin. Oncol. 39, 3140–3148 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bristol Meyers Squibb. Phase 3 CheckMate -901 trial [press release] https://go.nature.com/453V69X (11 July 2023).

  9. Becker, R. E. N. et al. Eur. Urol. 79, 364–371 (2021).

    Article  CAS  PubMed  Google Scholar 

  10. Mazza, P. et al. J. Urol. 200, 1005–1013 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  11. O'Donnell, P. H. et al. J. Clin. Oncol. 41, 4107–4117 (2023).

    Article  CAS  PubMed  Google Scholar 

  12. Rose, K. M. et al. J. Clin. Oncol. 41, LBA445 (2023).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

    Roger Li

  2. Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

    Roger Li

Authors
  1. Roger Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger Li.

Ethics declarations

Competing interests

R.L. declares research support from Predicine, Veracyte, CG Oncology, Valar Labs and Merck. R.L. declares positions on the clinical trial protocol committee for CG Oncology, and scientific advisor and/or consultant positions at Bristol Meyers Squibb, Merck, Fergene, Arquer Diagnostics, Urogen Pharma, Lucence, CG Oncology and Janssen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, R. Organ-sparing precision treatment for muscle-invasive bladder cancer. Nat Med 29, 2709–2710 (2023). https://doi.org/10.1038/s41591-023-02575-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02575-2

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing